Literature DB >> 12902621

A Canadian cohort study of cognitive impairment and related dementias (ACCORD): study methods and baseline results.

H Feldman1, A R Levy, G-Y Hsiung, K R Peters, A Donald, S E Black, R W Bouchard, S G Gauthier, D A Guzman, D B Hogan, A Kertesz, K Rockwood.   

Abstract

The overall objective of the Canadian Collaborative Cohort of Related Dementias (ACCORD) study is to describe the diagnostic distribution, natural history and treatment outcomes of individuals referred from the community to dementia clinics in Canada. Between 1997 and 1999, an inception cohort of 1,136 subjects entered into this longitudinal study. At the baseline assessment, 10.9% of the subjects were classified as "not cognitively impaired" (NCI), 30.1% as "cognitively impaired not demented" (CIND), and 59% as demented. A subclassification of CIND included amnestic 25.1%, vascular cognitive impairment 18.1%, psychiatric 17.2%, neurologic 7.3%, medical/toxic metabolic 3.5%, mixed 7.6% and not specified 19.0%. The percentage of the cohort referred with dementia increased progressively each decade, while the proportions of CIND and NCI decreased. Within the dementia group, Alzheimer's disease accounted for 47.2% of the subjects, mixed dementias 33.7%, vascular dementia 8.7%, frontotemporal degenerations 5.4%, dementia with Lewy bodies 2.5%, and unclassifiable 1.8%. The ACCORD cohort will allow a detailed study of the longitudinal course of CIND, and the longer-term outcomes of both treated and untreated dementia subjects. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12902621     DOI: 10.1159/000071189

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  35 in total

Review 1.  Advances in understanding the molecular basis of frontotemporal dementia.

Authors:  Rosa Rademakers; Manuela Neumann; Ian R Mackenzie
Journal:  Nat Rev Neurol       Date:  2012-06-26       Impact factor: 42.937

Review 2.  Treatment approaches to symptoms associated with frontotemporal degeneration.

Authors:  Tiffany W Chow
Journal:  Curr Psychiatry Rep       Date:  2005-10       Impact factor: 5.285

3.  Visual rating versus volumetry to detect frontotemporal dementia.

Authors:  T W Chow; F Gao; K A Links; J E Ween; D F Tang-Wai; J Ramirez; C J M Scott; M Freedman; D T Stuss; S E Black
Journal:  Dement Geriatr Cogn Disord       Date:  2011-05-31       Impact factor: 2.959

4.  Frontotemporal Dementia: A Cross-Cultural Perspective.

Authors:  Chiadi U Onyike; Shunichiro Shinagawa; Ratnavalli Ellajosyula
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 5.  The epidemiology of frontotemporal dementia.

Authors:  Chiadi U Onyike; Janine Diehl-Schmid
Journal:  Int Rev Psychiatry       Date:  2013-04

Review 6.  Fused in Sarcoma Neuropathology in Neurodegenerative Disease.

Authors:  Ian R A Mackenzie; Manuela Neumann
Journal:  Cold Spring Harb Perspect Med       Date:  2017-12-01       Impact factor: 6.915

Review 7.  Diagnosis and treatment of dementia: 3. Mild cognitive impairment and cognitive impairment without dementia.

Authors:  Howard Chertkow; Fadi Massoud; Ziad Nasreddine; Sylvie Belleville; Yves Joanette; Christian Bocti; Valérie Drolet; John Kirk; Morris Freedman; Howard Bergman
Journal:  CMAJ       Date:  2008-05-06       Impact factor: 8.262

Review 8.  The molecular genetics and neuropathology of frontotemporal lobar degeneration: recent developments.

Authors:  Ian R A Mackenzie; Rosa Rademakers
Journal:  Neurogenetics       Date:  2007-09-06       Impact factor: 2.660

Review 9.  Diagnosis and treatment of dementia: 2. Diagnosis.

Authors:  Howard H Feldman; Claudia Jacova; Alain Robillard; Angeles Garcia; Tiffany Chow; Michael Borrie; Hyman M Schipper; Mervin Blair; Andrew Kertesz; Howard Chertkow
Journal:  CMAJ       Date:  2008-03-25       Impact factor: 8.262

Review 10.  Vascular dementia: prevention and treatment.

Authors:  Catherine McVeigh; Peter Passmore
Journal:  Clin Interv Aging       Date:  2006       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.